60 Degrees Pharmaceuticals Inc Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $1.1M+82.9% YoYTTM through 30 Jun 2026
Net Income -$8.1MTTM through 30 Jun 2026
Free Cash Flow -$8.9MTTM through 30 Jun 2026
Margins
| Current | |
|---|---|
| Gross Margin | 22.3% |
| EBITDA Margin | -769.3% |
| Operating Margin | -772.1% |
| Net Margin | -729.9% |
Returns
-186.3%ROE
-137.3%ROA
Balance Sheet Health
Debt / Equity0.04x
Current Ratio2.66x
Net Debt-$2.1Mnet cash position
Cash & Equivalents$1M
Quality Metrics
Altman Z-Score-21.61
Piotroski F-Score1 / 9
FCF Margin-800.6%
Earnings-Beat Rate25.0%
Multi-Year Trend
RevenueFY2025: $1M
Diluted EPS-$2.67TTMFY2025: $-10.99
Dividend
No dividend
Capital Allocation
Capex Intensity10.8%
Segment Performance
| Segment | Revenue | YoY | Outlook |
|---|---|---|---|
| Product Sales | $1M | +65.4% | View detailsFocusing on expanding commercial reach via pharmacy partnerships (e.g., GoodRx, Runway Health) and clinical trials for new indications such as babesiosis. |
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.